NRAS and Miyoshi myopathy: These events may include mutations in key genes that when estimated as % of the tumor population emerge as subclonal events in different MM patients: KRAS (20–72%), NRAS (32–96%), BRAF (36–92%) or DIS3 genes (29–81%) [38].